Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PHLDB2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PHLDB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PHLDB2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PHLDB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PHLDB2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PHLDB2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PHLDB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00487629 | Skin | AK | mesenchymal cell differentiation | 40/1910 | 236/18723 | 9.16e-04 | 7.50e-03 | 40 |
GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00514977 | Skin | AK | negative regulation of stress fiber assembly | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:00018379 | Skin | AK | epithelial to mesenchymal transition | 29/1910 | 157/18723 | 1.15e-03 | 8.86e-03 | 29 |
GO:00303367 | Skin | AK | negative regulation of cell migration | 53/1910 | 344/18723 | 1.52e-03 | 1.10e-02 | 53 |
GO:00322327 | Skin | AK | negative regulation of actin filament bundle assembly | 10/1910 | 35/18723 | 2.00e-03 | 1.35e-02 | 10 |
GO:005149418 | Skin | AK | negative regulation of cytoskeleton organization | 29/1910 | 163/18723 | 2.08e-03 | 1.39e-02 | 29 |
GO:00328865 | Skin | AK | regulation of microtubule-based process | 39/1910 | 240/18723 | 2.32e-03 | 1.53e-02 | 39 |
GO:00321024 | Skin | AK | negative regulation of response to external stimulus | 61/1910 | 420/18723 | 2.96e-03 | 1.87e-02 | 61 |
GO:00108126 | Skin | AK | negative regulation of cell-substrate adhesion | 15/1910 | 68/18723 | 3.07e-03 | 1.92e-02 | 15 |
GO:00109273 | Skin | AK | cellular component assembly involved in morphogenesis | 20/1910 | 107/18723 | 5.45e-03 | 3.02e-02 | 20 |
GO:00353133 | Skin | AK | wound healing, spreading of epidermal cells | 6/1910 | 19/18723 | 9.42e-03 | 4.60e-02 | 6 |
GO:0042060111 | Skin | SCCIS | wound healing | 63/919 | 422/18723 | 2.26e-15 | 6.00e-12 | 63 |
GO:0034329110 | Skin | SCCIS | cell junction assembly | 52/919 | 420/18723 | 7.89e-10 | 5.23e-07 | 52 |
GO:0007044110 | Skin | SCCIS | cell-substrate junction assembly | 20/919 | 95/18723 | 2.78e-08 | 7.00e-06 | 20 |
GO:0031589110 | Skin | SCCIS | cell-substrate adhesion | 44/919 | 363/18723 | 3.03e-08 | 7.00e-06 | 44 |
GO:0150115111 | Skin | SCCIS | cell-substrate junction organization | 20/919 | 101/18723 | 8.21e-08 | 1.18e-05 | 20 |
GO:0007160110 | Skin | SCCIS | cell-matrix adhesion | 32/919 | 233/18723 | 1.38e-07 | 1.70e-05 | 32 |
GO:004001315 | Skin | SCCIS | negative regulation of locomotion | 44/919 | 391/18723 | 2.61e-07 | 2.61e-05 | 44 |
GO:0010810111 | Skin | SCCIS | regulation of cell-substrate adhesion | 30/919 | 221/18723 | 4.35e-07 | 3.67e-05 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHLDB2 | SNV | Missense_Mutation | novel | c.1172N>T | p.Asp391Val | p.D391V | Q86SQ0 | protein_coding | deleterious(0) | benign(0.203) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3502N>A | p.Asp1168Asn | p.D1168N | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.359N>A | p.Gly120Glu | p.G120E | Q86SQ0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1708N>G | p.Ile570Val | p.I570V | Q86SQ0 | protein_coding | tolerated(0.1) | benign(0.255) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.604C>T | p.Pro202Ser | p.P202S | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.549) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PHLDB2 | SNV | Missense_Mutation | | c.1690N>C | p.Glu564Gln | p.E564Q | Q86SQ0 | protein_coding | deleterious(0.05) | benign(0.388) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1608N>T | p.Arg536Ser | p.R536S | Q86SQ0 | protein_coding | tolerated(0.07) | benign(0.057) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.3134N>T | p.Ala1045Val | p.A1045V | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.7N>A | p.Glu3Lys | p.E3K | Q86SQ0 | protein_coding | deleterious_low_confidence(0) | benign(0.214) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3132N>T | p.Gln1044His | p.Q1044H | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |